Skip to main content

Table 3 Most frequent on-treatment adverse events (≥3% any treatment group) intent-to-treat population

From: Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial

n (%)

FF 100mcg (n = 51)

FF/VI 100/25mcg (n = 51)

Placebo (n = 51)

Headache

11 (22)

5 (10)

9 (18)

Oropharyngeal pain

2 (4)

2 (4)

2 (4)

Nasopharyngitis

2 (4)

0

3 (6)

Cough

3 (6)

0

1 (2)

Chest discomfort

0

0

3 (6)

Mouth ulceration

2 (4)

2 (4)

0

Nausea

2 (4)

0

2 (4)

Dysphonia

2 (4)

2 (4)

0

Hot flush

0

2 (4)

0

Seasonal allergy a

2 (4)

0

0

  1. aOne subject (2%) had seasonal allergy, reported as allergic rhinitis, during each treatment period.
  2. FF = fluticasone furoate; VI = vilanterol.